S-ClassAbout S-Class
C
CAPRAI Stock Diagnostic Report
Capricor upgraded at Oppenheimer as Deramiocel review extended
Oppenheimer has upgraded its investment rating on Capriola Therapeutics (CAPR) following the extension of the FDA review for DeramioCell.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$6.800000190734863Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support2.96 — echo this pre-calculated value verbatim, do NOT change it
Near-Term Resistance8.29 — echo this pre-calculated value verbatim, do NOT change it
02
FUNDAMENTALS
Financial & Fundamental Analysis
The upgrade of investment opinion by Oppenheimer and the market expectations reflected due to the FDA's extension of the key pipeline review period are noted; however, specific financial metrics changes or visible indicators directly linked to performance improvement are not included in this report.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $6.80 is positioned between the 20-day low support level ($2.96) and the high resistance level ($8.29). Given the high trading volume and RSI, it is important to closely monitor whether the resistance level will be broken and to test the support level in the event of a short-term correction.
Support2.96 — echo this pre-calculated value verbatim, do NOT change it
Resistance8.29 — echo this pre-calculated value verbatim, do NOT change it
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Oppenheimer has upgraded its investment rating in line with the extension of the FDA review period for the lead pipeline product, Deramiocel, which is acting as a direct catalyst for the increase.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-25)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.